Kiniksa Pharmaceuticals International, plc
KNSANasdaqHealthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $677.6M | $423.2M | $270.3M | $220.2M | $38.5M | — |
| Operating income | $77.2M | −$45.6M | −$25.2M | $9.8M | −$156.6M | −$157.4M |
| Net income | $59.0M | −$43.2M | $14.1M | $183.4M | −$157.9M | −$161.4M |
| Total assets | $763.6M | $580.6M | $526.3M | $459.7M | $232.8M | $349.5M |
| Total liabilities | $196.0M | $142.1M | $87.5M | $63.5M | $47.8M | $37.5M |
| Equity | $567.6M | $438.4M | $438.8M | $396.1M | $185.0M | $311.9M |
| EPS (diluted) | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 |
| Shares out. | 79.0M | 71.4M | 71.9M | 70.4M | 68.6M | 61.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 11.4%
- Net margin
- 8.7%
- Return on equity
- 10.4%
- Return on assets
- 7.7%
- Return on capital (ROCE)
- 12.4%
- Liabilities / assets
- 25.7%
- Debt / equity
- 0.35×
- Book value / share
- $7.19
- Revenue growth (YoY)
- 60.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.08safe
- Accruals / assets
- −10.3%clean
- Beneish M-Score
- -3.16normal
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2/3Recruitingreadout ~2027-12-31Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
- Phase 2Recruitingreadout ~2027-12-31Transition to KPL-387 Monotherapy Dosing & Administration Study
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Baker Bros. Advisors LpActivist (13D)May 26, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Rubric Capital Management LpPassive (13G)Feb 13, 2026
- Blackrock, Inc.Passive (13G)Jul 17, 2025
- Tang Capital Management LlcPassive (13G)Apr 4, 2025
- Fairmount Funds Management LlcPassive (13G)Feb 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Paolini John F.Officer — CHIEF MEDICAL OFFICER | May 1, 2026 | Option exercise | 58,424 | $10.36 |
| Patel Sanj KOfficer — CHAIRMAN & CEO | May 1, 2026 | Option exercise | 48,565 | $30.93 |
| Patel Sanj KOfficer — CHAIRMAN & CEO | Apr 28, 2026 | Option exercise | 431,904 | $10.36 |
| Quart Barry DDirector | Apr 28, 2026 | Option exercise | 13,099 | $14.33 |
| Megna Michael ROfficer — CHIEF ACCOUNTING OFFICER | Apr 9, 2026 | Sell | 6,625 | $46.69 |
| Moat RossOfficer — CHIEF OPERATING OFFICER | Apr 9, 2026 | Sell | 1,703 | $46.69 |
| Tessari EbenOfficer — CHIEF STRATEGY OFFICER | Apr 7, 2026 | Option exercise | 2,726 | — |
| Ragosa MarkOfficer — CHIEF FINANCIAL OFFICER | Apr 7, 2026 | Option exercise | 2,694 | — |
| Patel Sanj KOfficer — CHAIRMAN & CEO | Apr 6, 2026 | Option exercise | 7,278 | $10.36 |
| Paolini John F.Officer — CHIEF MEDICAL OFFICER | Apr 7, 2026 | Option exercise | 2,497 | — |
| Moat RossOfficer — CHIEF OPERATING OFFICER | Apr 6, 2026 | Sell | 2,367 | $48.58 |
| Megna Michael ROfficer — CHIEF ACCOUNTING OFFICER | Apr 7, 2026 | Option exercise | 3,932 | $1.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.2M | 5.5 | -10.0% |
| Apr 30, 2026 | 3.5M | 3.2 | -13.8% |
| Apr 15, 2026 | 4.1M | 7.2 | +0.1% |
| Mar 31, 2026 | 4.1M | 6.8 | +8.6% |
| Mar 13, 2026 | 3.8M | 5.1 | +11.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Shareholder voteMay 29, 2026
- Entered a material agreementMay 26, 2026
- Director / officer changeMay 1, 2026
- Results of operationsApr 28, 2026
- Results of operationsFeb 24, 2026
- Director / officer changeJan 14, 2026
- Results of operationsJan 12, 2026
- Results of operationsOct 28, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.